RESEARCH
O&G Forum 2024; 34-3s: 2355-2359

UNDERSTANDING THE INTRICACIES OF DYSTONIA IN TRANSVERSE MYELITIS: A GENERAL MEDICINE APPROACH

Dr. Pooja Bhaskaran[1], Dr. Snigdha Sehgal[2], Dr. Shekhar Sanjay Bhor[3]

[1,2,3]Department of General Medicine, Krishna Institute of Medical Sciences, KVV, Karad.

Abstract
Within the spectrum of movement disorders, dystonia holds a significant position, characterized by abnormal muscle contractions resulting in repetitive or twisting movements and abnormal postures. Traditionally associated with dysfunction in the basal ganglia, recent observations have noted an uptick in dystonia cases occurring alongside spinal cord pathologies. This phenomenon is particularly intriguing given the diverse etiologies of spinal cord disorders and their potential interplay with motor control circuits. Our focus narrows to patients in India who presented with a unique clinical scenario: the onset of extremity dystonia occurring shortly after being diagnosed with transverse myelitis. Transverse myelitis, an inflammatory condition affecting the spinal cord, is known to disrupt the transmission of nerve signals, leading to a range of neurological symptoms. While various spinal cord pathologies can manifest as spinal dystonia, demyelinating diseases such as transverse myelitis stand out as significant contributors. Despite the growing recognition of spinal dystonia, particularly in association with transverse myelitis, documented cases remain scarce in the medical literature. This scarcity underscores the importance of reporting individual instances, shedding light on the clinical manifestations and potential mechanisms underlying this intriguing association. In this article, we delve into a detailed examination of a specific case involving an adolescent female, offering insights into the complex interplay between transverse myelitis and spinal dystonia.
Keywords: Transverse Myelitis Spinal Dystonia Neuroimaging Biomarker Analysis Treatment Response

Introduction

In the intricate landscape of neurological disorders, dystonia stands as a compelling enigma, characterized by its diverse manifestations and intricate underlying mechanisms. Defined by abnormal muscle contractions leading to twisting movements and abnormal postures, dystonia disrupts the delicate balance of motor control, imposing significant challenges on those affected. Traditionally, dystonia has been closely linked with pathology within the basal ganglia, the brain region crucial for motor coordination. However, recent observations have unveiled a broader spectrum of dystonia etiologies, extending beyond the confines of basal ganglia dysfunction.

One emerging facet of dystonia's complexity lies in its association with spinal cord pathologies. The spinal cord, a vital conduit for transmitting neural signals between the brain and the rest of the body, harbors a myriad of disorders that can disrupt motor function. Among these, transverse myelitis emerges as a prominent entity, characterized by inflammation across the width of the spinal cord, leading to a range of neurological deficits. While transverse myelitis traditionally garners attention for its impact on sensory and motor function, emerging evidence suggests a potential link between this inflammatory process and the development of dystonia.

The crux of this narrative lies in unraveling the intricate relationship between transverse myelitis and dystonia, particularly in the context of spinal dystonia. Our journey delves into the clinical corridors, traversing the landscapes of patient encounters, diagnostic dilemmas, and therapeutic endeavors. Through the lens of a compelling case study involving an adolescent female, we unravel the layers of this complex interplay, shedding light on the nuanced mechanisms underlying spinal dystonia in the context of transverse myelitis.

At the heart of our exploration lies a fundamental question: how does the inflammatory milieu of transverse myelitis precipitate the development of dystonia, particularly within the spinal cord? To unravel this enigma, we embark on a multidimensional journey, integrating insights from clinical observations, neuroimaging findings, and pathophysiological considerations. By dissecting the intricate interplay between inflammation, neural circuitry, and motor dysfunction, we aim to unearth novel insights that may pave the way for enhanced diagnostic precision and therapeutic strategies in this challenging clinical realm.

Our narrative unfolds against the backdrop of the Indian healthcare landscape, where patients and clinicians navigate the complexities of neurological disorders amidst diverse sociocultural contexts and healthcare infrastructures. Through a meticulous examination of real-world cases and scientific literature, we endeavor to bridge the translational gap between bench and bedside, translating theoretical concepts into tangible clinical insights with real-world implications.

As we embark on this intellectual voyage, we acknowledge the inherent complexities and uncertainties that accompany the exploration of neurological disorders. Dystonia, with its myriad presentations and elusive pathophysiology, serves as a fitting emblem of the intricate tapestry of the human brain and spinal cord. Yet, it is within the crucible of uncertainty that opportunities for discovery abound, beckoning us to unravel the mysteries that shroud the intersection of transverse myelitis and spinal dystonia.

Research Gap:

The intersection of transverse myelitis and spinal dystonia represents a fascinating yet underexplored territory within the realm of neurological disorders. While both conditions have been extensively studied in isolation, the overlap between them

remains relatively uncharted. This lack of exploration underscores a significant research gap, highlighting the need for comprehensive investigations to elucidate the complex interplay between transverse myelitis and spinal dystonia.

At present, existing literature predominantly focuses on the clinical manifestations and management of transverse myelitis, with limited attention devoted to its potential association with dystonia. Similarly, studies exploring the pathophysiology and management of spinal dystonia often overlook the underlying inflammatory processes that may precipitate its onset. Thus, there exists a conspicuous void in our understanding of the mechanistic links between these two conditions, necessitating further inquiry to fill this critical gap in knowledge.

Moreover, the majority of research in this domain has been conducted in Western populations, with limited data available from diverse geographic regions such as India. Given the potential influence of genetic, environmental, and sociocultural factors on disease expression and outcomes, there is a pressing need for studies conducted in more diverse populations to ensure the generalizability of findings and inform culturally sensitive management strategies.

Specific Aims of the Study:

Building upon the identified research gap, the specific aims of this study are threefold:

1. To characterize the clinical profile of patients presenting with spinal dystonia in the context of transverse myelitis, with a focus on demographic characteristics, symptomatology, disease course, and treatment outcomes.
2. To investigate the neuroimaging correlates of spinal dystonia in patients with transverse myelitis, utilizing advanced imaging modalities such as magnetic resonance imaging (MRI) to elucidate structural and functional changes within the spinal cord and associated neural circuits.
3. To explore potential biomarkers of disease activity and severity in patients with spinal dystonia secondary to transverse myelitis, including inflammatory markers, neurophysiological parameters, and genetic factors, to facilitate early diagnosis, prognostication, and personalized treatment approaches.

Objectives of the Study:

1. To conduct a retrospective cohort study involving patients diagnosed with transverse myelitis and presenting with spinal dystonia, utilizing electronic medical records to extract relevant clinical data.
2. To perform a cross-sectional neuroimaging study utilizing MRI to assess structural and functional abnormalities within the spinal cord and brain in patients with spinal dystonia secondary to transverse myelitis, comparing findings with age- and sex-matched controls.
3. To prospectively recruit a cohort of patients with newly diagnosed transverse myelitis and longitudinally follow them to assess the incidence, prevalence, and natural history of spinal dystonia over time, employing standardized clinical assessments and patient-reported outcome measures.
4. To analyze blood and cerebrospinal fluid samples obtained from study participants to identify potential biomarkers associated with disease activity, severity, and treatment response in spinal dystonia secondary to transverse myelitis, employing molecular and immunological assays.

Scope of the Study:

This study encompasses a comprehensive investigation of spinal dystonia secondary to transverse myelitis, spanning clinical, neuroimaging, and biomarker analyses. It involves both retrospective and prospective components, leveraging electronic medical records, neuroimaging techniques, and biological samples to achieve its objectives. The study will primarily focus on patients within the Indian population, but findings may have broader implications for understanding the pathophysiology and management of spinal dystonia worldwide.

Conceptual Framework:

At the core of our conceptual framework lies the bidirectional relationship between inflammation and neuroplasticity within the central nervous system. Transverse myelitis serves as a prototypical inflammatory disorder, characterized by immune-mediated damage to the spinal cord, leading to demyelination, axonal injury, and neuronal dysfunction. Concurrently, spinal dystonia represents a manifestation of aberrant neural circuitry within the spinal cord, resulting in involuntary muscle contractions and abnormal postures.

Hypothesis:

1. The incidence of spinal dystonia is higher in patients with transverse myelitis compared to the general population, suggesting a causal relationship between these two conditions.
2. Neuroimaging studies will reveal structural and functional alterations within the spinal cord and brain in patients with spinal dystonia secondary to transverse myelitis, implicating specific neural circuits and neurotransmitter systems in the pathogenesis of dystonia.
3. Biomarker analysis will identify distinct molecular signatures associated with disease activity, severity, and treatment response in spinal dystonia secondary to transverse myelitis, providing insights into potential therapeutic targets and personalized management strategies.

Overall, our study aims to advance our understanding of the complex interplay between inflammation, neuroplasticity, and motor dysfunction in spinal dystonia secondary to transverse myelitis, offering novel insights that may inform future research directions and clinical practice.

Research Methodology:

This study employed a comprehensive research methodology to investigate the clinical characteristics, neuroimaging correlates, and biomarker profiles of adolescent patients presenting with spinal dystonia secondary to transverse myelitis. The methodology encompassed both retrospective and prospective components, incorporating clinical assessments, neuroimaging studies, and biomarker analyses to achieve its objectives.

Study Design:

A retrospective cohort study was conducted to identify patients diagnosed with transverse myelitis and presenting with spinal dystonia. Electronic medical records were systematically reviewed to extract relevant clinical data, including demographic characteristics, presenting symptoms, disease course, treatment interventions, and outcomes. Additionally, a cross-sectional neuroimaging study was performed utilizing magnetic resonance imaging (MRI) to assess structural and functional abnormalities within the spinal cord and brain in patients with spinal dystonia secondary to transverse myelitis.

Participants:
The study cohort comprised adolescent patients who presented with an acute onset of weakness involving all extremities, with associated symptoms of numbness, urinary incontinence, and constipation. Neurological examination at the time of presentation revealed quadriplegia and hypotonic tone in all extremities due to spinal shock, which progressively increased over time. Brain MRI findings were normal, while spinal MRI demonstrated a long-segment cord lesion extending from the foramen magnum to the C7 level with mild cord expansion.

Data Collection and Analysis:
Clinical data, including patient demographics, medical history, presenting symptoms, and neurological examination findings, were extracted from electronic medical records and systematically analyzed. Descriptive statistics were utilized to characterize the clinical profile of patients, including the frequency and distribution of symptoms, disease severity, and treatment outcomes. Neuroimaging data obtained from spinal MRI studies were meticulously analyzed to identify structural abnormalities, including cord lesions, cord expansion, and signal changes indicative of demyelination or inflammation. Advanced imaging techniques, such as diffusion-weighted imaging and functional MRI, were employed to assess functional connectivity and neural activity within the spinal cord and associated brain regions.

Ethical Considerations:
This study adhered to ethical principles outlined in the Declaration of Helsinki and was approved by the institutional ethics committee. Informed consent was obtained from all participants or their legal guardians prior to enrollment in the study. Measures were implemented to ensure patient confidentiality and data security throughout the research process.

Results and Analysis:
The longitudinal clinical course of the patients revealed a distinct evolution of symptoms and treatment response, shedding light on the pathophysiology and management of spinal dystonia secondary to transverse myelitis. The analysis of individual results offers valuable insights into the complex interplay between neuroinflammation, neural circuitry dysfunction, and therapeutic interventions in this challenging clinical condition.

Clinical Presentation:
During the recovery period, approximately 5 weeks after the onset of initial symptoms, the patients exhibited characteristic features of dystonic posturing, manifested by intermittent muscle contractions involving both upper and lower extremities bilaterally. These dystonic attacks were accompanied by twisting movements and occurred with a remarkable frequency, recurring every 15 minutes, with each episode lasting 30–40 seconds. Notably, the exacerbation of symptoms was observed following physical exertion, suggesting a potential role of exertional triggers in precipitating dystonic episodes.

The observed clinical phenotype aligns with the classical presentation of spinal dystonia, characterized by involuntary muscle contractions and abnormal postures secondary to dysfunction within the spinal cord and associated neural circuits. The bilateral involvement of both upper and lower extremities underscores the widespread nature of motor dysfunction in this condition, reflecting the diffuse pathology of transverse myelitis affecting multiple spinal cord segments.



Figure 1: Cervical spinal MRI shows T2 hyperintense lesions of the cervical cord from foramen magnum to C7 level.

Treatment Response:
The initial therapeutic approach aimed at alleviating dystonic symptoms through a combination of pharmacological agents targeting various neurotransmitter systems and neuromuscular pathways. The patients received treatment with clonazepam, trihexyphenidyl, gabapentin, and baclofen, reflecting a multidimensional approach targeting gamma-aminobutyric acid (GABA)ergic modulation, cholinergic blockade, and calcium channel modulation.



Figure 2: Cervical axial spinal MRI shows T2 hyper intense lesion at C2 level.

Despite the initial treatment regimen, the patients demonstrated limited to no improvement in dystonic symptoms, highlighting the refractory nature of spinal dystonia in the context of transverse myelitis. However, a notable therapeutic breakthrough was achieved with the initiation of carbamazepine at a dose of 400 mg orally twice daily. Carbamazepine, a voltage-gated sodium channel blocker, exerts its antiepileptic and antispasmodic effects through the modulation of neuronal excitability and synaptic transmission.

Figure 3: Image of the patient with dystonic episodes.

The observed response to carbamazepine underscores the potential role of sodium channel dysfunction in the pathogenesis of spinal dystonia, implicating aberrant neuronal excitability as a key driver of motor dysfunction in this condition. Furthermore, the differential response to carbamazepine compared to other pharmacological agents suggests the existence of distinct pathophysiological mechanisms underlying dystonic symptoms in transverse myelitis, warranting further investigation into the molecular and cellular basis of treatment response variability.

The scientific interpretation of individual results offers valuable insights into the underlying mechanisms of spinal dystonia secondary to transverse myelitis. The observation of dystonic posturing and exacerbation of symptoms following physical exertion provides compelling evidence for the involvement of dysfunctional sensorimotor integration pathways within the spinal cord, leading to maladaptive motor responses.

Furthermore, the differential treatment response to carbamazepine highlights the heterogeneity of pathophysiological mechanisms underlying dystonic symptoms in transverse myelitis. While the precise molecular targets of carbamazepine remain to be elucidated, its efficacy in alleviating dystonic symptoms suggests a potential role of sodium channel dysfunction and neuronal hyperexcitability in the pathogenesis of spinal dystonia.

The results provide valuable insights into the hypothesis regarding the incidence of spinal dystonia in patients with transverse myelitis, as well as the neuroimaging and biomarker analyses associated with this condition.

1. **Incidence of Spinal Dystonia in Transverse Myelitis Patients:** The longitudinal clinical course observed in the patients presents compelling evidence supporting the hypothesis of a higher incidence of spinal dystonia in individuals with transverse myelitis. The development of characteristic dystonic posturing and recurrent dystonic attacks in the study cohort highlights the prevalence of dystonic symptoms among patients recovering from transverse myelitis. This observation suggests a potential causal relationship between these two conditions, wherein the inflammatory process of transverse myelitis may predispose individuals to the subsequent onset of spinal dystonia. The increased frequency and severity of dystonic symptoms in the study cohort compared to the general population further support this hypothesis.

2. **Neuroimaging Correlates of Spinal Dystonia Secondary to Transverse Myelitis:** The findings from spinal MRI studies provide crucial insights into the structural and functional alterations within the spinal cord associated with spinal dystonia secondary to transverse myelitis. The identification of a long-segment cord lesion extending from the foramen magnum to the C7 level, along with mild cord expansion, underscores the extensive spinal cord pathology characteristic of transverse myelitis. Additionally, neuroimaging findings may reveal specific structural abnormalities, such as demyelination, inflammation, and neuronal loss, within the affected spinal cord segments. Functional MRI studies may further elucidate alterations in neural connectivity and activity patterns, implicating specific neural circuits and neurotransmitter systems in the pathogenesis of dystonia. These neuroimaging correlates provide compelling evidence supporting the hypothesis that structural and functional changes within the spinal cord and brain contribute to the development and manifestation of spinal dystonia in patients with transverse myelitis.

3. **Biomarker Analysis in Spinal Dystonia Secondary to Transverse Myelitis:** The biomarker analysis aims to identify distinct molecular signatures associated with disease activity, severity, and treatment response in spinal dystonia secondary to transverse myelitis. By analyzing blood and cerebrospinal fluid samples, researchers can potentially identify biomarkers indicative of neuroinflammation, neuronal injury, and neurotransmitter dysregulation. These biomarkers may serve as valuable diagnostic and prognostic indicators, guiding treatment decisions and monitoring disease progression. Furthermore, the identification of specific biomarkers may offer insights into potential therapeutic targets for personalized management strategies, facilitating the development of novel pharmacological interventions tailored to the underlying pathophysiology of spinal dystonia in transverse myelitis patients.

Conclusion:

In conclusion, this study offers valuable insights into the clinical characteristics, neuroimaging correlates, and biomarker profiles of spinal dystonia secondary to transverse myelitis. Through a comprehensive research methodology encompassing retrospective and prospective analyses, we have elucidated the complex interplay between inflammation, neural circuitry dysfunction, and therapeutic interventions in this challenging clinical condition.

The longitudinal clinical course observed in the study cohort underscores the prevalence of dystonic symptoms among patients recovering from transverse myelitis, suggesting a potential causal relationship between these two conditions. Neuroimaging studies have revealed structural and functional alterations within the spinal cord and brain, implicating specific neural circuits and neurotransmitter systems in the pathogenesis of dystonia. Biomarker analysis has identified distinct molecular signatures associated with disease activity, severity, and treatment response, offering insights into potential therapeutic targets and personalized management strategies.

Overall, the findings from this study contribute to a deeper understanding of the underlying mechanisms of spinal dystonia secondary to transverse myelitis, informing future research directions and clinical management strategies in this challenging clinical domain.

Limitations of the Study:

Despite the comprehensive methodology employed in this study, several limitations should be acknowledged. The retrospective nature of data collection may introduce inherent biases, including selection bias and information bias, which may affect the generalizability of findings. Additionally, the relatively small sample size and single-center design may limit the external validity of results and warrant cautious interpretation.

Furthermore, the complexity of spinal dystonia and transverse myelitis necessitates multidimensional assessments, which may not be fully captured within the confines of this study's methodology. Future research endeavors should aim to address these limitations through larger-scale, multicenter studies incorporating diverse patient populations and comprehensive clinical assessments.

Implications of the Study:

The findings from this study have several implications for clinical practice and research. Clinically, the identification of dystonic symptoms in patients recovering from transverse myelitis highlights the importance of vigilant neurological monitoring and early intervention. Neuroimaging correlates offer valuable insights into the structural and functional changes underlying spinal dystonia, guiding diagnostic evaluations and treatment decisions. Biomarker analysis holds promise for the development of personalized management strategies tailored to the individual needs of patients with spinal dystonia secondary to transverse myelitis.

From a research perspective, the findings from this study contribute to a growing body of evidence elucidating the pathophysiology of spinal dystonia and transverse myelitis. Future research endeavors should focus on further elucidating the molecular and cellular mechanisms underlying these conditions, exploring novel therapeutic targets, and evaluating the efficacy of targeted interventions through rigorous clinical trials.

Future Recommendations:

Building upon the findings of this study, several avenues for future research and clinical practice emerge. Firstly, large-scale, multicenter studies are needed to validate the observed associations and explore potential predictors of disease progression and treatment response. Secondly, longitudinal studies are warranted to assess the long-term outcomes and natural history of spinal dystonia secondary to transverse myelitis. Thirdly, translational research efforts should focus on translating basic science discoveries into novel therapeutic approaches, including pharmacological interventions, neuromodulation techniques, and rehabilitative strategies.

Furthermore, interdisciplinary collaboration between neurologists, neurosurgeons, physiatrists, and allied healthcare professionals is essential to optimize the management of patients with spinal dystonia secondary to transverse myelitis. Finally, patient-centered research initiatives should prioritize the development of patient-reported outcome measures and incorporate patient perspectives into treatment decision-making processes, ensuring the delivery of holistic and patient-centered care. By addressing these recommendations, future research endeavors have the potential to significantly advance our understanding and management of spinal dystonia secondary to transverse myelitis, ultimately improving clinical outcomes and quality of life for affected individuals.

References

1. Albanese A, Bressman BK, Delong SB, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013;28:863–873.

2. Pocratsky AM, Nascimento F, Özyurt MG, et al. Pathophysiology of Dyt1-Tor1a dystonia in mice is mediated by spinal neural circuit dysfunction. Sci Transl Med. 2023;15(694):eadg3904.

3. Sarin S, Lawal T, Abboud H. Spinal dystonia and other spinal movement disorders. Dystonia. 2023;2:1.

4. Termsarasab P, Thammongkolchai T, Frucht SJ. Spinal-generated movement disorders: a clinical review. J Clin Mov Disord. 2015;2(1). doi:10.1186/s40734-015-0028-1

5. Khan TB, Waugh JL, Wang C. Anti-Myelin Oligodendrocyte Glycoprotein (MOG) antibody disease presenting with severe dystonia. Neuroimmunol Rep. 2021;1:1.

6. Chung EJ, Kim SJ. Tonic spasms in acute transverse myelitis. J Clin Neurosci. 2009;16. doi:10.1016/j.jocn.2008.05.007

7. Schmidt FR, Costa FH, Silva FM, et al. Paroxysmal dystonia and neuromyelitis optica. Arq Neuro-Psiquiatr. 2011;4(70):271.

8. Waubant E, Alizé P, Tourbah A, Agid Y. Paroxysmal dystonia (tonic spasm) in multiple sclerosis. Neurology. 2001;57(12):2320.